1. Nenad Filipović, Univerzitet u Kragujevcu (FIN, PMF, FMN), Serbia
Cardiovascular diseases are leading causes of death in the Europe. SILICOFCM is a multi-modular, innovative in silico clinical trials platform for the design and functional optimization of whole heart performance and monitoring effectiveness of pharmacological treatment, with the aim to reduce animal studies and human clinical trials. The SILICOFCM platform is based on the integrated multidisciplinary and multiscale methods for analysis of patient-specific data and development of patient-specific models for monitoring and assessment of patient condition through the course of disease.
In this platform fluid-structure coupling for left ventricle was introduced. A nonlinear material model for heart wall using constitutive curves which include the stress-strain relationship was presented.
Monodomain model of modified FitzHugh-Nagumo model of the cardiac cell was used. Six electrodes are positioned at the chest to model the precordial leads and the results are compared with real clinical measurements. Inverse ECG method was used to optimize potential on the heart. A whole heart electrical activity in the torso embedded environment, with spontaneous initiation of activation in the sinoatrial node, incorporating a specialized conduction system with heterogeneous action potential morphologies throughout the heart was presented. Body surface potential maps in a healthy subject during progression of ventricular activation in nine sequences were used.
The results with parametric and realistic model of left ventricle where PV (pressure/volume) diagrams depend on the change of Ca2+, elasticity of the wall and the inlet and outlet velocity profile have been presented. It directly affects the ejection fraction.
The presented approach with variation of LV geometry and simulations which include influence of different parameters on the PV diagrams are directly interlinked with drug effects on heart function. SILICOFCM platform includes incorporation of different drugs that directly affect the cardiac PV diagrams and ejection fraction (e.g., angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, nitrates, diuretics, calcium channel blockers). Computational platform like SILICOFCM for sure will open a new avenue for in silico clinical trials as well as a new tool for risk prediction of cardiac disease to specific patient using drug therapy.
SIMPOZIJUM B - Biomaterijali i nanomedicina